News › Clinical Practice, Industry News, Patient Care

Promising Phase 2 Data of CCH for Cellulite Published

March 28, 2019

Phase 2 data of Endo International’s collagenase clostridium histolyticum (CCH) for the treatment of cellulite, published in Dermatologic Surgery (February 28, 2019), demonstrate that CCH delivered clinically meaningful and statistically significant improvement as compared to placebo for all primary and secondary endpoints.
The Phase 2 clinical trial enrolled 375 women aged 18 years or older (mean age 46.5), who were randomized to receive up to three treatment sessions of CCH (0.84 mg/session, n=189) or placebo (n=186), with each treatment session occurring approximately 21 days apart. Twelve injections were administered into cellulite dimples during each session across an entire treatment area (left or right buttock, or left or right posterior thigh).Read more at MedEsthetics >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Allergan Aesthetics Receives Approval for Boey® (trenibotulinumtoxinE) in Canada
    • SafeLink Consulting Becomes Platinum Vendor Affiliate with the American Med Spa Association
    • Allergan Aesthetics’ Skinvive by Juvéderm Receives FDA Approval for the Improvement of Neck Appearance
    • Obagi Medical Announces FDA Approval of Obagi saypha ChIQ Injectable Hyaluronic Acid Gel
    • MedSafe Becomes Gold Vendor Affiliate with the American Med Spa Association